CryoLife Pursues SynerGraft Heart Valve Trial, ACL, Vascular Applications
This article was originally published in The Gray Sheet
Executive Summary
CryoLife's clinical trial for the firm's SynerGraft replacement heart valve would enroll 150 pediatric patients over a 12-18 month period and possibly extend the study after the first 6-12 months to include adults.